Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Axitinib + SSGJ-707 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Axitinib | Inlyta | AG-013736|AG013736 | KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 VEGFR Inhibitor (Pan) 36 | Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov). |
| SSGJ-707 | PF-08634404|SSGJ 707|SSGJ707|PF08634404|PF 08634404 | PD-L1/PD-1 antibody 137 VEGF Antibody 17 | SSGJ-707 (PF-08634404) is a bispecific antibody that targets PDCD1 (PD-1) and VEGF, which potentially decreases tumor growth (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_3). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07227415 | Phase Ib/II | SSGJ-707 Ipilimumab + SSGJ-707 Axitinib + SSGJ-707 | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Recruiting | USA | ESP | AUS | 2 |